10-QPeriod: Q3 FY2003

QUEST DIAGNOSTICS INC Quarterly Report for Q3 Ended Sep 30, 2003

Filed October 31, 2003For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) reported strong financial results for the quarter ended September 30, 2003. Net revenues increased by 15.3% year-over-year, driven by the significant acquisition of Unilab Corporation and solid average revenue per requisition growth, which was supported by a shift towards higher-value gene-based testing. Operating income also saw a substantial improvement, reaching 17.8% of net revenues, up from 14.9% in the prior year, reflecting effective cost management and efficiency gains from Six Sigma initiatives. The company also announced its intention to initiate quarterly cash dividends, starting at $0.15 per share in January 2004, and expanded its share repurchase authorization, signaling confidence in its financial health and commitment to returning value to shareholders. While the company faces ongoing integration of Unilab and the complexities of HIPAA transaction standards, its financial performance indicates a positive trajectory.

Key Highlights

  • 1Net revenues grew 15.3% to $1,221.2 million for the quarter, fueled by the Unilab acquisition and increased average revenue per requisition.
  • 2Operating income increased significantly to $217.5 million, representing 17.8% of net revenues, up from 14.9% in the prior year, due to revenue growth and efficiency improvements.
  • 3Net income for the quarter rose to $120.0 million, or $1.12 per diluted share, compared to $86.6 million, or $0.87 per diluted share, in the same period last year.
  • 4The acquisition of Unilab Corporation was completed in February 2003, adding substantial goodwill and contributing to revenue and volume growth.
  • 5Quest Diagnostics announced its Board of Directors approved the payment of a quarterly cash dividend of $0.15 per common share, payable in January 2004.
  • 6The company expanded its share repurchase program authorization by an additional $300 million, demonstrating confidence in its financial position and commitment to shareholder returns.
  • 7Average revenue per requisition improved by 3.8% due to a shift in test mix towards higher-value services and a favorable payer mix, partially offset by the inclusion of Unilab's lower revenue per requisition.

Frequently Asked Questions

The acquisition of Unilab Corporation, completed in February 2003, was a significant driver of Quest Diagnostics' financial results. It contributed to a 15.3% increase in net revenues for the quarter and added approximately 12.5% to overall testing volume growth. The acquisition also led to a substantial increase in goodwill on the balance sheet. Integration costs are expected, but the company anticipates significant synergy benefits.

Quest Diagnostics is initiating a quarterly cash dividend of $0.15 per common share, with the first payment expected in January 2004. Additionally, the company has significantly expanded its share repurchase authorization, signaling confidence in its ability to generate cash flow and commitment to enhancing shareholder value.

Revenue growth is primarily driven by the Unilab acquisition and an increase in average revenue per requisition. The improvement in average revenue per requisition is attributed to a strategic shift towards higher-value testing, such as gene-based testing, and a favorable change in payer mix. Profitability improvements are largely due to operational efficiencies realized through Six Sigma and standardization initiatives, leading to better cost management.

The company faces ongoing integration challenges with Unilab. Additionally, the implementation of HIPAA transaction standards presents complexity and potential disruptions in cash flow and ongoing reimbursements, although the company is working with payers and pursuing contingency plans. Ongoing legal proceedings and potential for substantial damages are also mentioned, though management believes current reserves and insurance are sufficient.